Biomea Fusion, Inc. (BMEA) presented 52‑week follow‑up data from its Phase II COVALENT‑111 study at the 19th International Conference on Advanced Technologies & Treatments for Diabetes in Barcelona on March 14 2026. Dr. Juan Pablo Frías delivered the oral presentation, highlighting the durability of icovamenib’s effects.
At Week 52, the 100 mg QD arm achieved a 1.5% reduction in HbA1c in the severe insulin‑deficient subgroup, while the overall severe insulin‑deficient cohort saw a 1.2% drop across all arms. These reductions persisted nine months after the 12‑week treatment period, underscoring the drug’s durable efficacy.
C‑peptide index increased by 53% in the severe insulin‑deficient subgroup and by 35% in the GLP‑1‑treated subgroup, demonstrating preserved endogenous insulin secretion and supporting the disease‑modifying potential of icovamenib.
The Phase II COVALENT‑111 study enrolled 267 patients, including 10 in the severe insulin‑deficient cohort and 6 in the 100 mg QD arm. The data reinforce Biomea’s strategy to launch two new Phase II studies (COVALENT‑211 and COVALENT‑212) targeting patients who responded best to icovamenib.
Biomea faces ongoing liquidity challenges, but the durable efficacy data could attract investment or partnership opportunities. Interim CEO Mick Hitchcock emphasized the therapeutic promise, stating, "We believe icovamenib demonstrates potential to transform the diabetes treatment landscape by effectively addressing the underlying biology."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.